These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 15072041)

  • 1. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical devices; 30-day notices and 135-day PMA (premarket approval application) supplement review--FDA. Direct final rule.
    Fed Regist; 1998 Apr; 63(80 Pt 1):20530-3. PubMed ID: 10179319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical devices; 30-day notices and 135-day PMA (premarket approval application) supplement review; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Apr; 63(80 Pt 1):20558-61. PubMed ID: 10179320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Final rule.
    Fed Regist; 1998 Oct; 63(195):54042-4. PubMed ID: 10185825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Dec; 64(232):67720-63. PubMed ID: 11010665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational new drug applications and new drug applications--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(28):6854-62. PubMed ID: 10177736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
    Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.